using a medical device to deliver oxygen and heal wounds

Our product features a dual component system, combining micro-nanobubble technology and negative pressure wound therapy.


Affordable | Prevents Infection | Wound Oxygenation | Tissue Recovery

WHY: Diabetic Foot Ulcers

Diabetes is the leading cause of non-traumatic lower extremity amputations in the United States. A diabetic foot ulcer (DFU) is a foot affected by an ulceration that is associated with neuropathy of the lower limb in a patient with diabetes. As of 2015, 30 million people in the United States suffer from diabetes, 25% will suffer from DFUs at least once in their diabetic health life. As a result more than 7.25 million people currently suffer from diabetic foot ulcers. To treat these DFUs, the costs are really high, treatments ranging from $11000-$16000, costing the nation a grand total of $10 billion dollars in annual healthcare costs.

At a compounded annual growth rate of 4.1%, the market value is expected to reach 14 billion dollars by 2024, compared to 10 billion dollars in 2015.


Bubtech aims to provide affordable treatment of diabetic foot ulcers and to prevent the need for amputations, improving overall patient quality of life.


Advised by Dr. Alan Widgerow at the Center for Tissue Engineering Dept of Plastic Surgery, University of California, Irvine


    Henry Samueli School of Engineering LogoUC Irvine Health LOGOUROP LOGOUCI Applied Innovation LogoCalPlug Logo

  • Keenan Ferguson

    3 Years Experience in Hardware

    Troubleshooting Expert

    MSE | Mechanical Design
  • Nikita Ganeshan

    Data Acquisition Expert

    Communications Background

    BME | Coding Optimization
  • Lauren Lastra

    4 Years Public Speaking

    Research Experience

    BME | Failure Analysis
  • Nitara Tariqi

    Strategic Vision Expert

    Conflict Resolution

    MSE | Product Design
  • Stephanie Yeh

    4 Years Aerospace Industry

    Graphic Design Background

    MSE | Graphic Design


Currently our competitors in the wound care market include companies that use methods involving negative pressure, cell graft, surgery and hyperbaric oxygen therapy. At Bubtech we are taking it a step further by introducing a rapid wound healing device that has improved dissolved oxygen content, promotes wound healing, costs very little, and has an incredibly low risk of infection.


The B.U.B system will be an initial investment purchase from hospitals.

    Bubtech-Market Strategy - Business Model

    Bubtech will be focused on obtaining partners and securing its federal supply schedule with VA Health Care during clinical trials. By the end of 2020, we hope to begin sales and pre-production in the United States. The device will be marketed at medical trade fairs which is how we expect to acquire distributors and manufacturing representatives. Those distributors and manufacturing representatives will sell to vascular surgeons, plastic surgeons and wound care centers in the United States at the markup prices demonstrated.


With a power suctioned pump, the B.U.B system classifies as a FDA Class II Special Controls device. This requires that only a 510(k) premarket notification be submitted along with clinical data to satisfy all regulatory requirements before commercialization can be achieved. The clinical trials needed are projected to be completed by the beginning of 2020.


For distribution and business opportunities feel free to reach out to us!